New Appointments to Supervisory Bodies of E. Merck KG, Darmstadt, Germany

- Frank Stangenberg-Haverkamp and Johannes Baillou become most senior representatives
- Jon Baumhauer retires for age reasons

Darmstadt, January 27, 2014 – E. Merck KG, Darmstadt, Germany, which combines the financial interests of the Merck family and is general partner of Merck KGaA, Darmstadt, Germany with an interest of 70%, announced today that at this year's General Partners' Meeting, the family partners elected their representatives to the Family Board, which is the supervisory body of E. Merck KG, Darmstadt, Germany.

Dr. Frank Stangenberg-Haverkamp (65) has been elected as the new Chairman of the twelve-member Family Board. Jon Baumhauer (69), previously Chairman of the Family Board and Chairman of the Executive Board of E. Merck KG, Darmstadt, Germany, has retired from his offices for age reasons.

“For decades, Jon Baumhauer has uniquely shaped and successfully led the company and the Merck family of owners. The partners are exceptionally grateful to him for his leadership of the community of family members and for preparing the next generation,” said Stangenberg-Haverkamp, praising the achievements of his predecessor.

Baumhauer was elected to the Board of Partners of E. Merck KG, Darmstadt, Germany, in 1979. In 1989 he became Vice Chairman of this body and from 1994 to 2004 he served...
News Release

as Chairman of the Board of Partners. In 2004, he took over the chairmanship of the
Family Board.

The Family Board newly appointed the nine members of the Board of Partners of
E. Merck KG, Darmstadt, Germany. The Board of Partners is comparable to the
supervisory board of a German stock corporation (AG). It supervises the executive
management of Merck KGaA, Darmstadt, Germany, and is responsible for the
appointment Executive Board members of Merck KGaA, Darmstadt, Germany,

Johannes Baillou (48) has been elected Chairman of the Board of Partners. He has been
a member of the Board of Partners since 2009 and served as Vice Chairman of this body
since then. Stangenberg-Haverkamp, who has been a member of the Board of Partners
since 1984, has been elected Vice Chairman. In addition, Dr. Wolfgang Büchele (54),
Dr. Siegfried Karjetta (59), Albrecht Merck (64), Prof. Dr. Helga Rübsamen-Schaeff (65),
Prof. Dr. Gregor Schulz (63), Prof. Dr. Theo Siegert (66), and Tobias Thelen (37) have
been elected to the Board of Partners.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a global pharmaceutical, chemical and life science company with total
revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000
employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. The
company’s operating activities come under the umbrella of Merck KGaA, Darmstadt, Germany, in which the
Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%.
In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever
since.

Worldwide there are two separate companies that bear the name “Merck”, the original Merck KGaA from
Darmstadt, Germany, the oldest pharmaceutical and chemical company in the world, and the pharmaceutical
company Merck & Co. in the United States. The rights to the name and trademark MERCK in North America
(USA and Canada) lie with Merck & Co., the former U.S. subsidiary of Merck, whereas Merck KGaA,
Darmstadt, Germany, operates in North America under the umbrella brand EMD. In the rest of the world,
Merck KGaA, Darmstadt, Germany, owns the rights to the Merck name and trademark. This press release
was distributed by Merck KGaA, Darmstadt, Germany.